Zachary Henry, DO
Internal Medicine · Fort Lauderdale, FLNPI 1972922730
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Gilead at 37.1% of the total. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 383 payments — averaging $59.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$9K
- Theratechnologies Inc.$8K
- Viiv Healthcare Company$3K
- Janssen Products, LP$918
- Johnson & Johnson$536
- Hologic Sales And Service, LLC$359
- plus $1K from 16 others
Across 129 payments — averaging $3184.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$142K
- GSK$126K
- Viiv Healthcare Company$74K
- Theratechnologies Inc.$69K
What the payments were for
- Consulting fees$10,81047%
- Grants$290%
- Travel & lodging$1,8278%
- Food & beverage$10,15844%
- Education$1491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 113 | $8,514 |
| Theratechnologies Inc. | 39 | $8,463 |
| Viiv Healthcare Company | 125 | $3,071 |
| Janssen Products, LP | 9 | $918 |
| Johnson & Johnson | 38 | $536 |
| Hologic Sales And Service, LLC | 21 | $359 |
| EMD Serono, Inc. | 9 | $336 |
| Madrigal Pharmaceuticals | 3 | $188 |
| Merck | 5 | $129 |
| VBI Vaccine (delaware) Inc. | 3 | $80 |
| Boston Scientific | 3 | $75 |
| GSK | 4 | $58 |
| AbbVie | 2 | $55 |
| Cook Medical LLC | 1 | $29 |
| Novavax Inc | 1 | $28 |
| Pfizer | 1 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| Napo Pharmaceuticals Inc | 1 | $21 |
| Alkermes, Inc. | 1 | $20 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,972 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 304 | $1,145,078 |
| Egrifta SvTesamorelin Acetate | 140 | $999,587 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 114 | $608,661 |
| TivicayDolutegravir Sodium | 239 | $551,139 |
| DescovyEmtricitabine/Tenofov Alafenam | 226 | $487,194 |
| DovatoDolutegravir Sodium/Lamivudine | 156 | $443,847 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 111 | $430,090 |
| CabenuvaCabotegravir/Rilpivirine | 65 | $415,881 |
| JulucaDolutegravir/Rilpivirine | 110 | $372,101 |
| PrezcobixDarunavir/Cobicistat | 125 | $305,054 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 69 | $252,971 |
| OzempicSemaglutide | 118 | $134,629 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 37 | $127,822 |
| IsentressRaltegravir Potassium | 38 | $74,366 |
| ZenpepLipase/Protease/Amylase | 14 | $58,177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $8,514 | $2,062,362641 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Cabenuva, Juluca, Triumeq | $3,071 | $2,035,938639 claims |
| Theratechnologies Inc.Egrifta Sv | $8,463 | $999,587140 claims |
| Janssen Products, LPSymtuza | $918 | $608,661114 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $536 | $317,059140 claims |
| MerckIsentress, Januvia, Janumet Xr | $129 | $110,746100 claims |
| Lilly USA, LLCTrulicity | $14 | $45,67750 claims |
| PfizerEliquis, Toviaz | $27 | $26,15545 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $58 | $23,01561 claims |
| AbbVieCreon | $55 | $15,17815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Fort Lauderdale
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Sheetal SharmaFort Lauderdale$184K
- Evan WuFort Lauderdale$114K
- Haytham ElgammalMiami$2.2M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.